Recent Updates
Recently added Catalysts
CRIS Positive Sentiment

Oncology Hematology West, PC dba Nebraska Cancer Specialists

Wednesday, October 23, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Oncology Hematology West, PC, operating as Nebraska Cancer Specialists, showcases its commitment to oncology through various patient studies, including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL. The company also highlights its diverse pipeline, which includes treatments like Emavusertib and Fimepinostat. Collaborations with partners further strengthen its research capabilities.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 51 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Company has a diverse pipeline of oncology treatments.
  • Engagement in multiple patient studies shows commitment to research.
  • Collaborations with partners enhance scientific research efforts.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are sponsored by Nebraska Cancer Specialists?

Nebraska Cancer Specialists sponsors studies like TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What is the focus of Nebraska Cancer Specialists' pipeline?

The pipeline includes treatments such as Emavusertib (CA-4948) and Fimepinostat.

How does Nebraska Cancer Specialists collaborate in research?

The company engages in partner collaborations to enhance its scientific research efforts.

What is the compassionate use policy?

Nebraska Cancer Specialists has a compassionate use policy to support patients in need.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare oncology TakeAim studies Emavusertib Fimepinostat
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →